Alisa Beth Goldberg, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 39 | 2023 | 475 | 8.720 |
Why?
|
| Misoprostol | 20 | 2023 | 94 | 7.190 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 16 | 2023 | 65 | 5.030 |
Why?
|
| Mifepristone | 14 | 2023 | 151 | 2.710 |
Why?
|
| Abortion, Spontaneous | 6 | 2023 | 539 | 2.210 |
Why?
|
| Pregnancy, Ectopic | 3 | 2023 | 146 | 1.770 |
Why?
|
| Abortifacient Agents, Steroidal | 6 | 2023 | 22 | 1.720 |
Why?
|
| Intrauterine Devices | 4 | 2023 | 117 | 1.670 |
Why?
|
| Intrauterine Devices, Medicated | 3 | 2023 | 30 | 1.590 |
Why?
|
| Intrauterine Devices, Copper | 2 | 2023 | 31 | 1.480 |
Why?
|
| Chorionic Gonadotropin | 5 | 2023 | 458 | 1.280 |
Why?
|
| Contraceptive Agents, Female | 4 | 2023 | 123 | 1.190 |
Why?
|
| Abortion, Legal | 5 | 2022 | 120 | 1.150 |
Why?
|
| Vacuum Curettage | 4 | 2018 | 44 | 1.020 |
Why?
|
| Pregnancy Trimester, First | 10 | 2023 | 921 | 0.940 |
Why?
|
| Pregnancy | 49 | 2023 | 30200 | 0.930 |
Why?
|
| Anesthetics, Intravenous | 3 | 2018 | 397 | 0.850 |
Why?
|
| Pregnancy Tests | 1 | 2023 | 33 | 0.840 |
Why?
|
| Pregnancy Trimester, Second | 6 | 2023 | 737 | 0.770 |
Why?
|
| Conscious Sedation | 3 | 2018 | 534 | 0.760 |
Why?
|
| Dilatation | 4 | 2023 | 313 | 0.750 |
Why?
|
| Lacerations | 1 | 2022 | 149 | 0.730 |
Why?
|
| Abortion, Therapeutic | 3 | 2016 | 35 | 0.680 |
Why?
|
| Minors | 2 | 2022 | 59 | 0.680 |
Why?
|
| Parental Consent | 1 | 2019 | 63 | 0.630 |
Why?
|
| Analgesia | 3 | 2013 | 460 | 0.580 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 117 | 0.570 |
Why?
|
| Pregnancy in Adolescence | 1 | 2019 | 166 | 0.570 |
Why?
|
| Naproxen | 1 | 2016 | 101 | 0.530 |
Why?
|
| Labor, Induced | 2 | 2011 | 156 | 0.520 |
Why?
|
| Dilatation and Curettage | 1 | 2015 | 53 | 0.510 |
Why?
|
| Ibuprofen | 2 | 2013 | 229 | 0.450 |
Why?
|
| Labor Stage, First | 1 | 2013 | 20 | 0.440 |
Why?
|
| Oxytocics | 2 | 2003 | 67 | 0.420 |
Why?
|
| Ketorolac | 1 | 2013 | 95 | 0.420 |
Why?
|
| Laminaria | 3 | 2015 | 4 | 0.410 |
Why?
|
| Aftercare | 2 | 2020 | 921 | 0.390 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2013 | 361 | 0.390 |
Why?
|
| Obstetric Labor Complications | 1 | 2013 | 243 | 0.360 |
Why?
|
| Levonorgestrel | 2 | 2023 | 80 | 0.360 |
Why?
|
| Administration, Intravaginal | 5 | 2016 | 149 | 0.360 |
Why?
|
| Men | 1 | 2010 | 65 | 0.340 |
Why?
|
| Pain | 4 | 2023 | 5103 | 0.340 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2010 | 117 | 0.330 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 227 | 0.330 |
Why?
|
| Female | 56 | 2023 | 397089 | 0.320 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 190 | 0.320 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2016 | 156 | 0.320 |
Why?
|
| Massachusetts | 9 | 2023 | 8902 | 0.320 |
Why?
|
| Fetal Death | 1 | 2011 | 438 | 0.320 |
Why?
|
| Midazolam | 3 | 2018 | 267 | 0.320 |
Why?
|
| Spouse Abuse | 1 | 2010 | 182 | 0.310 |
Why?
|
| Cervical Ripening | 2 | 2005 | 18 | 0.310 |
Why?
|
| Terminology as Topic | 1 | 2015 | 1539 | 0.300 |
Why?
|
| Contraceptives, Postcoital | 1 | 2007 | 15 | 0.300 |
Why?
|
| Pregnancy, Unwanted | 1 | 2007 | 24 | 0.300 |
Why?
|
| Contraception, Postcoital | 1 | 2007 | 21 | 0.290 |
Why?
|
| Reminder Systems | 1 | 2010 | 387 | 0.280 |
Why?
|
| Fentanyl | 3 | 2018 | 450 | 0.280 |
Why?
|
| Hysteroscopy | 1 | 2007 | 62 | 0.280 |
Why?
|
| Pregnancy, Unplanned | 1 | 2007 | 86 | 0.280 |
Why?
|
| Young Adult | 20 | 2023 | 60049 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2276 | 0.270 |
Why?
|
| Postpartum Period | 2 | 2011 | 1197 | 0.270 |
Why?
|
| Uterine Diseases | 1 | 2007 | 108 | 0.270 |
Why?
|
| Social Stigma | 3 | 2018 | 785 | 0.270 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 2188 | 0.250 |
Why?
|
| Sexual Partners | 1 | 2010 | 806 | 0.250 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 2961 | 0.230 |
Why?
|
| Ultrasonography | 3 | 2013 | 6001 | 0.230 |
Why?
|
| Adult | 31 | 2023 | 223640 | 0.220 |
Why?
|
| Rh Isoimmunization | 1 | 2023 | 23 | 0.220 |
Why?
|
| Contraception | 3 | 2020 | 362 | 0.220 |
Why?
|
| Humans | 56 | 2023 | 768393 | 0.220 |
Why?
|
| Double-Blind Method | 6 | 2016 | 12456 | 0.220 |
Why?
|
| Retrospective Studies | 12 | 2023 | 81801 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2018 | 13052 | 0.210 |
Why?
|
| Pain Measurement | 4 | 2018 | 3581 | 0.210 |
Why?
|
| Administration, Oral | 4 | 2016 | 4039 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2012 | 3231 | 0.190 |
Why?
|
| Midwifery | 1 | 2003 | 130 | 0.190 |
Why?
|
| Adolescent | 16 | 2020 | 89184 | 0.190 |
Why?
|
| Hypnotics and Sedatives | 1 | 2009 | 1188 | 0.180 |
Why?
|
| Single-Blind Method | 2 | 2018 | 1585 | 0.180 |
Why?
|
| Anesthetics | 1 | 2006 | 525 | 0.180 |
Why?
|
| Faculty | 1 | 2023 | 384 | 0.170 |
Why?
|
| Gestational Age | 6 | 2023 | 3615 | 0.170 |
Why?
|
| Cervix Uteri | 1 | 2003 | 577 | 0.160 |
Why?
|
| Patient Satisfaction | 6 | 2018 | 3486 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2010 | 2189 | 0.150 |
Why?
|
| Time Factors | 9 | 2016 | 40272 | 0.150 |
Why?
|
| Curriculum | 2 | 2023 | 3776 | 0.140 |
Why?
|
| Outpatients | 2 | 2023 | 1604 | 0.140 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 156 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 419 | 0.140 |
Why?
|
| Desogestrel | 1 | 2016 | 18 | 0.130 |
Why?
|
| Injections, Intramuscular | 2 | 2016 | 556 | 0.130 |
Why?
|
| Pregnancy Rate | 3 | 2016 | 655 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2006 | 1765 | 0.130 |
Why?
|
| Treatment Failure | 3 | 2016 | 2663 | 0.130 |
Why?
|
| Professional Practice Location | 1 | 2015 | 57 | 0.130 |
Why?
|
| Professional Role | 1 | 2018 | 316 | 0.120 |
Why?
|
| Estradiol | 1 | 2002 | 1952 | 0.120 |
Why?
|
| Obesity | 1 | 2017 | 13084 | 0.120 |
Why?
|
| Gender Identity | 1 | 2021 | 770 | 0.120 |
Why?
|
| Erythrocytes | 1 | 2023 | 2421 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2015 | 386 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 2226 | 0.100 |
Why?
|
| Treatment Outcome | 9 | 2018 | 65379 | 0.100 |
Why?
|
| Logistic Models | 3 | 2019 | 13323 | 0.090 |
Why?
|
| Cross Infection | 1 | 2020 | 1426 | 0.090 |
Why?
|
| Prevalence | 3 | 2023 | 15872 | 0.090 |
Why?
|
| Communication Aids for Disabled | 1 | 2010 | 56 | 0.090 |
Why?
|
| Coercion | 1 | 2010 | 68 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 41795 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2023 | 54920 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2784 | 0.080 |
Why?
|
| Telemetry | 1 | 2010 | 200 | 0.080 |
Why?
|
| Poverty Areas | 1 | 2010 | 269 | 0.080 |
Why?
|
| Nurses | 1 | 2018 | 2494 | 0.080 |
Why?
|
| Health Policy | 1 | 2020 | 2698 | 0.070 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2007 | 83 | 0.070 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 145 | 0.070 |
Why?
|
| Education, Medical | 1 | 2018 | 1742 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2015 | 2258 | 0.070 |
Why?
|
| Tissue Adhesions | 1 | 2007 | 223 | 0.070 |
Why?
|
| Language | 1 | 2015 | 1558 | 0.060 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 969 | 0.060 |
Why?
|
| Women | 1 | 2007 | 226 | 0.060 |
Why?
|
| United States | 7 | 2023 | 73150 | 0.060 |
Why?
|
| Lorazepam | 1 | 2006 | 155 | 0.060 |
Why?
|
| United States Food and Drug Administration | 2 | 2003 | 1672 | 0.060 |
Why?
|
| Students, Medical | 1 | 2018 | 1964 | 0.060 |
Why?
|
| Intraoperative Period | 1 | 2005 | 513 | 0.060 |
Why?
|
| Patient Preference | 1 | 2011 | 947 | 0.060 |
Why?
|
| San Francisco | 1 | 2004 | 166 | 0.060 |
Why?
|
| Informed Consent | 1 | 2010 | 1010 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2011 | 22296 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8562 | 0.050 |
Why?
|
| Drug Utilization | 1 | 2007 | 1191 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3922 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 240 | 0.050 |
Why?
|
| Dinoprostone | 1 | 2003 | 597 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 715 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2023 | 855 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 26375 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2004 | 643 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 941 | 0.040 |
Why?
|
| Oxytocin | 1 | 2003 | 403 | 0.040 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 147 | 0.040 |
Why?
|
| Federal Government | 1 | 2020 | 266 | 0.040 |
Why?
|
| Depersonalization | 1 | 2018 | 40 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 6318 | 0.040 |
Why?
|
| Administration, Buccal | 2 | 2008 | 14 | 0.040 |
Why?
|
| Medical Records | 1 | 2004 | 1412 | 0.040 |
Why?
|
| Placebos | 1 | 2002 | 1668 | 0.040 |
Why?
|
| State Government | 1 | 2020 | 389 | 0.040 |
Why?
|
| Boston | 1 | 2010 | 9371 | 0.040 |
Why?
|
| Algorithms | 1 | 2018 | 14154 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2016 | 24318 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39407 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2006 | 6350 | 0.030 |
Why?
|
| Decision Making | 1 | 2010 | 3953 | 0.030 |
Why?
|
| Checklist | 1 | 2023 | 844 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2018 | 395 | 0.030 |
Why?
|
| Risk Factors | 4 | 2020 | 74962 | 0.030 |
Why?
|
| Equipment Design | 1 | 2004 | 3529 | 0.030 |
Why?
|
| Middle Aged | 3 | 2018 | 223491 | 0.030 |
Why?
|
| Women's Health | 1 | 2003 | 2078 | 0.030 |
Why?
|
| Reoperation | 1 | 2004 | 4341 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2002 | 2693 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3707 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 5512 | 0.020 |
Why?
|
| Risk | 1 | 2023 | 9636 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 4047 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2016 | 2931 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 3438 | 0.020 |
Why?
|
| Burnout, Professional | 1 | 2018 | 712 | 0.020 |
Why?
|
| Child | 1 | 2017 | 80891 | 0.020 |
Why?
|
| Polyvinyl Alcohol | 1 | 2007 | 74 | 0.020 |
Why?
|
| Magnesium Sulfate | 1 | 2007 | 73 | 0.020 |
Why?
|
| Administration, Rectal | 1 | 2006 | 69 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2006 | 151 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 10377 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2020 | 5099 | 0.020 |
Why?
|
| El Salvador | 1 | 2005 | 34 | 0.020 |
Why?
|
| Telemedicine | 1 | 2020 | 3107 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2006 | 1642 | 0.010 |
Why?
|
| Education | 1 | 2005 | 535 | 0.010 |
Why?
|
| Pandemics | 1 | 2022 | 8753 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 15881 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2011 | 3131 | 0.010 |
Why?
|
| Polymers | 1 | 2007 | 1630 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2007 | 1704 | 0.010 |
Why?
|
| Educational Status | 1 | 2005 | 2518 | 0.010 |
Why?
|
| Male | 2 | 2018 | 364902 | 0.010 |
Why?
|